Optionally fused heterocyclyl- substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

A compound of Formula (I)

• or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein:
• Y is NR;
• R is selected from the group consisting of hydrogen, C1-4 alkyl, C1-4 haloalkyl, and C1-4 hydroxyalkyl;
• or
• or R and R2 in combination with the pyrimidine ring of formula (I) form a substituted or unsubstituted pyrrolo[2,3-d]pyrimidine ring or a substituted or unsubstituted 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine ring;
• or
• R2 and R3a in combination with the pyrimidine ring of formula (I) form a substituted or unsubstituted pyrrolo[2,3-d]pyrimidine ring or a substituted or unsubstituted 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine ring;
• R1 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, and substituted or unsubstituted C1-4 alkoxy;
• R4a is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, —CN, C1-C6 alkoxy, C1-6 haloalkoxy, C3-C5 cycloalkyl, heteroaryl and aryl.
• R4b is selected from the group consisting of, oxo, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-C4 alkoxy, and C1-4 haloalkoxy;
• R5 is selected from the group consisting of —(CR8R9)pOR12, —(CR8R9)p-CR13R14R15, —(CR8R9)p-C(═O)OR7, and —(CR8R9)p-C(═O)NR8R9;
• n and p are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
• R6a is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, and substituted or unsubstituted aryl;
• R6b is selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted aryl-C1-6 alkyl, substituted or unsubstituted C2-9 heteroalicyclyl-C1-6 alkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted aryl;
• R7, R8, R9, and R12, are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted aryl-C1-6 alkyl, substituted or unsubstituted heteroaryl-C1-6 alkyl and substituted or unsubstituted aryl;
• R13 is absent, or selected from the group consisting of hydrogen, —CN, —CH3, fluorine, —OH, —CH2OH, —OCH3, —CH2CH2OH, —CO2H, —CO2—C1-4-alkyl, —CH2—SO2R20 and —CONR8R9 wherein R8 and R9 are independently of each other selected from hydrogen, C1-4 alkyl, C1-4 aminoalkyl, or R8 and R9 are combined to form a C2-C6 heteroalicyclyl, and R20 is selected from C1-6 alkyl;
• R14 and R15 are independently selected from the group consisting of hydrogen, and substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl;
• or R14 and R15 are combined to form a ring system selected from the group consisting of substituted or unsubstituted C3-7 cycloalkyl, substituted or unsubstituted C3-7cycloalkenyl, substituted or unsubstituted C2-6 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
• B is a ring system selected from the group aryl or heteroaryl;
• R3a is selected from the group consisting of C1-4 alkyl, C1-4 alkylene-C3-6 cycloalkyl, C1-4 alkylene-C3-6 heteroalicyclyl, C3-6 cycloalkyl, and C3-5 heteroalicyclyl, any of which may be substituted or unsubstituted;
• R3b is selected from the group consisting of hydrogen, substituted or unsubstituted C1-4 alkyl, —(CH2)1-4—C(═O)R10, C1-4 alkylene-C3-6 cycloalkyl, C1-4 alkylene-C3-6 heteroalicyclyl, C3-6 cycloalkyl, and C3-6 heteroalicyclyl.
• R3c is selected from the group consisting of hydrogen, C1-4 alkyl, and C3-6 cycloalkyl, and with the proviso that the compound is not